Select Language
IDO1
IDO1 Overview
| English Name | Indoleamine 2,3-dioxygenase | Approved Drugs | 0 |
| Drugs in Clinical Trials | 11 | Target Synonym | Indoleamine-pyrrole 2，3-dioxygenase，IDO1，IDO-1，INDO，IDO，Indoleamine-Pyrrole 2，3 Dioxygenase，Indole 2，3-Dioxygenase，EC 1.13.11.52，Indoleamine-Pyrrole 2，3，-Dioxygenase，Indoleamine 2，3-Dioxygenase 1，Indolamine 2，3 Dioxygenase，EC:1.13.11.52 |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | Indoleamine 2,3-dioxygenase |
| Target Synonym | Indoleamine-pyrrole 2，3-dioxygenase，IDO1，IDO-1，INDO，IDO，Indoleamine-Pyrrole 2，3 Dioxygenase，Indole 2，3-Dioxygenase，EC 1.13.11.52，Indoleamine-Pyrrole 2，3，-Dioxygenase，Indoleamine 2，3-Dioxygenase 1，Indolamine 2，3 Dioxygenase，EC:1.13.11.52 |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 11 |
| Highest Development Stage | Phase 3 Clinical |
IDO1 Product List
- Product Category
Protein (1)
- Product Status
Launched (1)
- Species
Human (1)
- Tag
His Tag (1)
- Conjugate
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
ID1-H5143 |  Human | E. coli | Human IDO1 Protein, His Tag (active enzyme, MALS verified) |  |  |  Add to Cart |
Total: 1
- 1
IDO1 Background
This gene encodes indoleamine 2,3-dioxygenase (IDO) - a heme enzyme that catalyzes the first and rate-limiting step in tryptophan catabolism to N-formyl-kynurenine. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme is thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity. Through its expression in dendritic cells, monocytes, and macrophages this enzyme modulates T-cell behavior by its peri-cellular catabolization of the essential amino acid tryptophan.[provided by RefSeq, Feb 2011]
IDO1 Synonyms
IDO, IDO-1, INDO
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Epacadostat | INCB-024360; 71596A9R13 (UNII code); INCB-24360 | Phase 3 Clinical | Incyte Corp | Abdominal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Glioma; Head and Neck Neoplasms; Leukemia, B-Cell; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell; Melanoma; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Sarcoma; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder N | Details |
| Puliginurad | YL-90148 | Phase 3 Clinical | YL-Pharma | Gout; Hyperuricemia | Details |
| Linrodostat | ONO-7701; BMS-986205 | Phase 3 Clinical | Bristol-Myers Squibb Company | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endometrial Neoplasms; Glioblastoma; Head and Neck Neoplasms; Laryngeal Diseases; Lung Neoplasms; Melanoma; Neoplasms; Oral Squamous Cell Carcinoma; Skin Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| HTX-201 | KHK-2455; HTX-201 | Phase 2 Clinical | Kyowa Hakko Kirin Co Ltd | Carcinoma; Carcinoma, Transitional Cell; Epstein-Barr Virus Infections; Neoplasms; Rejection of renal transplantation; Solid tumours | Details |
| IO-102 | IO-102 | Phase 2 Clinical | Herlev Hospital, Io Biotech Aps, Merck Sharp & Dohme Corp | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Melanoma; Oral Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma (OPSCC) | Details |
| (-)-Epigallocatechin gallate | AB-4166 | Phase 2 Clinical | Charite Universitaetsmedizin Berlin | Alzheimer Disease; Colonic Neoplasms; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Frailty; Glaucoma, Open-Angle; Huntington Disease; Hypertension; Idiopathic Pulmonary Fibrosis; Inflammation; Insulin Resistance; Leukemia; Liver Cirrhosis; Lung Diseases, Interstitial; Multiple Sclerosis, Relapsing-Remitting; Muscular Dystrophy, Duchenne; Neoplasms; Obesity; Ocular Hypertension; Papillomavirus Infections; Parkinson Disease; Peripheral Nervous System Diseases; Prostatic Neoplasms; Uterine Cervical Diseases | Details |
| Indoximod | 1-MT; D-1MT; NLG-001; NLG-8189; NSC-721782 | Phase 2 Clinical | Newlink Genetics Co | Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Diffuse Intrinsic Pontine Glioma; Ependymoma; Glioblastoma; Glioma; Gliosarcoma; Leukemia, Myeloid, Acute; Lung Neoplasms; Medulloblastoma; Melanoma; Metastatic breast cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
| RiMO-301 | RiMO-301 | Phase 2 Clinical | The University Of Chicago | Head and Neck Neoplasms; Neoplasms | Details |
| SHR-9146 | HTI-1090; SHR-9146 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Neoplasms; Solid tumours | Details |
| LPM-3480226 | LY-01013; LPM-3480226 | Phase 1 Clinical | Luye Pharma Group Ltd | Solid tumours | Details |
| TQB-3562 | TQB-3562 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd | Solid tumours | Details |
- Overview
- Product List
- Clinical Drug Information
Share to: